MY139546A - 5ht4 partial agonist pharmaceutical compositions - Google Patents

5ht4 partial agonist pharmaceutical compositions

Info

Publication number
MY139546A
MY139546A MYPI20024825A MYPI20024825A MY139546A MY 139546 A MY139546 A MY 139546A MY PI20024825 A MYPI20024825 A MY PI20024825A MY PI20024825 A MYPI20024825 A MY PI20024825A MY 139546 A MY139546 A MY 139546A
Authority
MY
Malaysia
Prior art keywords
pharmaceutical compositions
partial agonist
weight
amount
agonist pharmaceutical
Prior art date
Application number
MYPI20024825A
Other languages
English (en)
Inventor
Jerome Aubert
Christian Vitzling
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MY139546A publication Critical patent/MY139546A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI20024825A 2001-12-21 2002-12-20 5ht4 partial agonist pharmaceutical compositions MY139546A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01403339A EP1321142A1 (en) 2001-12-21 2001-12-21 Solid pharmaceutical composition for oral administration of Tegaserod

Publications (1)

Publication Number Publication Date
MY139546A true MY139546A (en) 2009-10-30

Family

ID=8183045

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20024825A MY139546A (en) 2001-12-21 2002-12-20 5ht4 partial agonist pharmaceutical compositions

Country Status (31)

Country Link
US (2) US20050106236A1 (enExample)
EP (2) EP1321142A1 (enExample)
JP (1) JP4718776B2 (enExample)
KR (1) KR100980144B1 (enExample)
CN (1) CN100464749C (enExample)
AR (1) AR037937A1 (enExample)
AT (1) ATE320807T1 (enExample)
AU (1) AU2002361198B2 (enExample)
BR (1) BR0215148A (enExample)
CA (1) CA2470668C (enExample)
CO (1) CO5640102A2 (enExample)
CY (1) CY1105559T1 (enExample)
DE (1) DE60210139T2 (enExample)
DK (1) DK1458377T3 (enExample)
EC (1) ECSP105163A (enExample)
EG (1) EG24194A (enExample)
ES (1) ES2258171T3 (enExample)
HU (1) HU226589B1 (enExample)
IL (2) IL162451A0 (enExample)
MX (1) MXPA04006157A (enExample)
MY (1) MY139546A (enExample)
NO (1) NO20042779L (enExample)
NZ (1) NZ533585A (enExample)
PE (1) PE20030872A1 (enExample)
PL (1) PL369509A1 (enExample)
PT (1) PT1458377E (enExample)
RU (1) RU2322978C2 (enExample)
SI (1) SI1458377T1 (enExample)
TW (1) TWI260221B (enExample)
WO (1) WO2003053432A1 (enExample)
ZA (1) ZA200404467B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL200132B1 (pl) * 1998-08-21 2008-12-31 Novartis Ag Zastosowanie 3-(5-metoksy-1H-indol-3-ilometyleno)-N-pentylokarbazyimidoamidu
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE602004007105T2 (de) 2003-01-28 2008-02-28 Microbia Inc., Cambridge Zusammensetzung zur behandlung von gastrointestinalen störungen
WO2004085393A1 (en) * 2003-03-25 2004-10-07 Hetero Drugs Limited Novel crystalline forms of tegaserod maleate
WO2004104577A2 (en) * 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
AR045081A1 (es) * 2003-07-24 2005-10-12 Novartis Ag Modificaciones estables de maleato de hidrogeno de tegaserod
PT1663182E (pt) 2003-09-12 2013-03-14 Amgen Inc Formulação de dissolução rápida de cinacalcet hcl
US20050165085A1 (en) * 2003-12-16 2005-07-28 Marioara Mendelovici Polymorphic forms of tegaserod base and salts thereof
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP3351248B1 (en) 2008-12-31 2021-06-09 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2880338A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
KR102287207B1 (ko) 2013-04-12 2021-08-09 알데릭스, 인코포레이티드 Nhe3-결합 화합물 및 포스페이트 수송을 저해하는 방법
CN104922083B (zh) * 2015-04-15 2017-12-22 湖南尔康湘药制药有限公司 磺胺嘧啶片及其制备方法
EA036204B1 (ru) * 2015-10-16 2020-10-14 Нобел Илач Санайи Ве Тиджарет А.Ш. Фармацевтические композиции нилотиниба гидрохлорида
JP2020505333A (ja) 2017-01-09 2020-02-20 アルデリックス， インコーポレイテッド Ｎｈｅ媒介性アンチポートの阻害薬
CN110267944B (zh) 2017-01-09 2024-03-08 阿德利克斯股份有限公司 可用于治疗胃肠道病症的化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
ATE220543T1 (de) * 1996-04-23 2002-08-15 Janssen Pharmaceutica Nv Rasch-freisetzende ph-unabhängige feste dosisformen enthaltend cisaprid
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
PL200132B1 (pl) * 1998-08-21 2008-12-31 Novartis Ag Zastosowanie 3-(5-metoksy-1H-indol-3-ilometyleno)-N-pentylokarbazyimidoamidu
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
AU3574500A (en) * 1999-03-25 2000-10-16 Yuhan Corporation Rapidly disintegrable tablet for oral administration
DE60039357D1 (de) * 1999-08-03 2008-08-14 Lilly Icos Llc Pharmazeutische zusammensetzung enthaltend tadalafil

Also Published As

Publication number Publication date
DE60210139D1 (de) 2006-05-11
CA2470668A1 (en) 2003-07-03
NZ533585A (en) 2006-04-28
KR100980144B1 (ko) 2010-09-03
IL162451A0 (en) 2005-11-20
JP4718776B2 (ja) 2011-07-06
ECSP105163A (es) 2010-07-30
AU2002361198A1 (en) 2003-07-09
NO20042779L (no) 2004-09-17
CO5640102A2 (es) 2006-05-31
AU2002361198B2 (en) 2006-06-08
SI1458377T1 (sl) 2006-08-31
EP1458377B1 (en) 2006-03-22
JP2005516946A (ja) 2005-06-09
RU2004122631A (ru) 2005-08-10
DK1458377T3 (da) 2006-06-12
ZA200404467B (en) 2006-05-31
KR20040066922A (ko) 2004-07-27
HUP0402492A3 (en) 2008-04-28
EG24194A (en) 2008-10-14
IL162451A (en) 2009-02-11
HU226589B1 (en) 2009-04-28
EP1458377A1 (en) 2004-09-22
TWI260221B (en) 2006-08-21
EP1321142A1 (en) 2003-06-25
WO2003053432A1 (en) 2003-07-03
US20090104263A1 (en) 2009-04-23
CN100464749C (zh) 2009-03-04
PE20030872A1 (es) 2003-11-24
PL369509A1 (en) 2005-04-18
MXPA04006157A (es) 2004-10-27
TW200410684A (en) 2004-07-01
CN1606438A (zh) 2005-04-13
HUP0402492A2 (hu) 2005-07-28
DE60210139T2 (de) 2006-08-17
US20050106236A1 (en) 2005-05-19
ES2258171T3 (es) 2006-08-16
AR037937A1 (es) 2004-12-22
PT1458377E (pt) 2006-07-31
CA2470668C (en) 2011-07-05
ATE320807T1 (de) 2006-04-15
RU2322978C2 (ru) 2008-04-27
BR0215148A (pt) 2004-10-19
CY1105559T1 (el) 2010-07-28

Similar Documents

Publication Publication Date Title
MY139546A (en) 5ht4 partial agonist pharmaceutical compositions
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
NO20053143L (no) Farmasoytiske sammensetninger omfattende en basisk, henholdsvis sur legemiddelforbindelse, en sufaktant og en fysiologisk akseptabel vannloselig syre henholdsvis base.
AP1739A (en) Azaindoles
MXPA04000456A (es) Analogos de prostaglandina como agonistas del receptor ep4.
BG108420A (en) New indole derivatives with 5-ht6 receptor affinity
KR960700708A (ko) 3,4-디아릴크로만을 이용한 뼈 손실의 억제방법(methdos for inhibiting bone loss with 3,4-diarylchroman)
ZA200104188B (en) Use of alpha-keto enamine derivaties as ingredients.
JO2339B1 (en) Benzamidazole compounds
TW200633730A (en) Oral disintegrating dosage forms
IL150986A0 (en) 1,2,3,4,- tetrahydroisoquinoline derivatives
TNSN07145A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
IL149496A (en) Pharmaceutical compositions and their use in the treatment of the gastrointestinal tract
IL179718A0 (en) Pharmaceutical composition containing irbesartan
MXPA03000548A (es) Combinacion novedosa de agonista (5-ht2) y antagonistas (5-ht6) de serotonina como formulacion farmaceutica.
NZ511085A (en) Oral pharmaceutical compositions containing buprenorphin
NO20034863L (no) Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser
SG162605A1 (en) Pharmaceutical compositions
PL1635792T3 (pl) Stabilne kompozycje farmaceutyczne pochodnych kwasu 2-aza-bicyklo[3.3.0]-oktano-3-karboksylowego
MY129314A (en) Pharmaceutical composition comprising sumatriptan
BR0315016A (pt) Composição fumìgena
MXPA05008711A (es) Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico.
WO2002055062A3 (en) Pharmaceutical tablet comprising paroxetine mesylate
TW200505504A (en) Saquinavir mesylate oral dosage form
CA2099585A1 (en) Pharmaceutical compositions